The FDA-cleared Apollo pulmonary evaluation software is a CT analysis application, generating repeatable measurements of lung structure and function.
Apollo advances VIDA’s quantitative approach to pulmonary disease analysis by incorporating lessons learned through multiple academic and clinical trials with its predecessor Pulmonary Workstation 2.0 (PW2).
Apollo strengthens VIDA’s solution for lung airway and parenchymal analysis with algorithmic, workflow and dataflow improvements for use in a high volume, time constrained clinical and clinical trial environment.
VIDA Diagnostics president and CEO Susan Wood said the increasing prevalence of COPD, and the growing requirement to objectively characterize disease and treatment response, increases the significance of quantitative imaging in evaluating COPD patients.
National Jewish Health Medicine professor and COPDGene principal investigator James Crapo said the work of COPDGene recognizes that COPD may not be a single disease, and therefore more directed therapies will be required to effectively treat the disease.
"Quantitative imaging applications, like Apollo, represent an emerging paradigm shift in evaluating patients with COPD, and have the promise to effectively classify COPD by disease subtype, enabling individualized treatment strategies," Crapo said.
